TESARO (TSRO) Price Target Lowered to $146.00 at Morgan Stanley
TESARO (NASDAQ:TSRO) had its target price decreased by Morgan Stanley from $156.00 to $146.00 in a report issued on Thursday. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would suggest a potential upside of 153.12% from the stock’s current price.
Several other research firms have also commented on TSRO. Credit Suisse Group restated an “outperform” rating and issued a $150.00 price target (down previously from $190.00) on shares of TESARO in a report on Thursday, January 18th. Barclays reduced their price target on shares of TESARO from $135.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday. Cowen reduced their price target on shares of TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a report on Tuesday, January 2nd. Jefferies Group restated a “hold” rating and issued a $124.00 price target on shares of TESARO in a report on Friday, November 3rd. Finally, BidaskClub upgraded shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $133.39.
Shares of TESARO (NASDAQ:TSRO) opened at $57.68 on Thursday. The stock has a market cap of $3,240.00, a PE ratio of -6.28 and a beta of 1.40. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a 52-week low of $52.20 and a 52-week high of $184.00.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares in the company, valued at approximately $690,529.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 40.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Delek Group Ltd. purchased a new stake in TESARO during the 4th quarter worth approximately $2,483,000. Iguana Healthcare Management LLC grew its position in TESARO by 40.0% during the 4th quarter. Iguana Healthcare Management LLC now owns 35,000 shares of the biopharmaceutical company’s stock worth $2,900,000 after purchasing an additional 10,000 shares during the last quarter. Element Capital Management LLC purchased a new stake in TESARO during the 4th quarter worth approximately $16,302,000. Kazazian Asset Management LLC grew its position in TESARO by 48.8% during the 4th quarter. Kazazian Asset Management LLC now owns 7,806 shares of the biopharmaceutical company’s stock worth $647,000 after purchasing an additional 2,560 shares during the last quarter. Finally, Macquarie Group Ltd. grew its position in TESARO by 36.6% during the 4th quarter. Macquarie Group Ltd. now owns 115,354 shares of the biopharmaceutical company’s stock worth $9,559,000 after purchasing an additional 30,895 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.